RSABE for HVD [RSABE / ABEL]

posted by Ravi  – India, 2009-03-13 08:21 (5907 d 22:57 ago) – Posting: # 3358
Views: 3,704

Dear All,

We have used a replicate crossover (4 period, 2 sequence) design for testing bioequivalence of one of our formulation. Two sequences used in the design were RTRT and TRTR.

Now my question is as CVintra for reference is well above .70 or 70% can we go for reference scaling average bioequivalence apporach (RSABE). We are going for US market.

One more question is that Can we apply RSABE if we have not specified this approach in the protocol and if yes is it acceptable to USFDA and if not what should be the alternative.

Waiting for ur invaluable comments and suggestions.

Thanks & Regards
Ravi Pandey

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
147 visitors (0 registered, 147 guests [including 12 identified bots]).
Forum time: 08:19 CEST (Europe/Vienna)

A statistical analysis, properly conducted, is a delicate dissection of
uncertainties, a surgery of suppositions.    Micheal J. Moroney

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5